pyrazines has been researched along with sch 1473759 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Basso, AD; Esposite, S; Gray, K; Hicklin, DJ; Kerekes, AD; Kirschmeier, P; Lee, S; Liang, L; Liu, M; Monsma, FJ; Ponery, A; Smith, EB; Tagat, JR; Tevar, S; Xiao, Y; Yu, T; Zhang, Y | 1 |
Ferraz Nogueira Filho, MA; Figg, WD; Helman, L; McCalla, A; Nguyen, J; Peer, CJ | 1 |
2 other study(ies) available for pyrazines and sch 1473759
Article | Year |
---|---|
SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Line, Tumor; Drug Administration Schedule; Female; Humans; Imidazoles; Kinesins; Male; Mice; Mice, Nude; Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Taxoids; Xenograft Model Antitumor Assays | 2011 |
A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma.
Topics: Administration, Oral; Animals; Aurora Kinase A; Aurora Kinase B; Biological Availability; Chromatography, High Pressure Liquid; Drug Stability; Half-Life; Imidazoles; Linear Models; Liquid-Liquid Extraction; Mice; Plasma; Pyrazines; Quality Control; Reproducibility of Results; Tandem Mass Spectrometry | 2017 |